Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study.
SARS-CoV-2
biologic therapy
mRNA vaccine
psoriasis
seroconversion
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
13
01
2022
accepted:
23
02
2022
pubmed:
27
2
2022
medline:
7
5
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)-based antisevere acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) vaccinations. To assess antibody formation and the incidence of side effects after anti-SARS-CoV-2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls. 102 moderate-to-severe psoriatic patients (56.2 [±13.5] years) and 55 age-matched healthy (56.4 ± 13.6 years) volunteers were included in our study. Ten to 21 days after the administration of the second dosage of BNT162b2 or mRNA-1273 vaccine, antibody levels specific to the SARS-CoV-2 spike (S) protein receptor binding domain were monitored. The incidence of postvaccination side effects was recorded and compared to real-life data in the literature. Of the 102 patients, 57 (55.88%) received tumor necrosis factor (TNF), 28 (27.45%) received interleukin (IL)-12/23, 16 (15.68%) received IL-17, and 1 (0.99%) received IL-23 inhibitors. No significant differences in the median serum level of anti-SARS-CoV-2S antibody were observed between the study population and the control group (median IQR range: 1681.0 U/mL (600.0-4844.0) versus 1984.0 U/mL (1000.0-3136.0; p = 0.82). The most frequent side effects of the mRNA vaccines within 7 days after the administration of both dosages were arm pain on the side of injection (23.53% and 23.53%), fatigue (9.80% and 13.72%), headache (4.9% and 5.88%), and chills or shivering (4.9% and 8.82%). Detectable antibodies against SARS-CoV-2S protein appear 10-21 days after the administration of the second dosage of BNT162b2 or mRNA-1273 vaccines in moderate-to-severe psoriatic patients receiving biologicals, similar to those of healthy controls.
Identifiants
pubmed: 35218276
doi: 10.1111/dth.15408
pmc: PMC9111760
doi:
Substances chimiques
Biological Products
0
COVID-19 Vaccines
0
RNA, Messenger
0
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15408Informations de copyright
© 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
Références
J Drugs Dermatol. 2013 Oct;12(10):1122-9
pubmed: 24085047
Dermatol Ther. 2022 May;35(5):e15408
pubmed: 35218276
J Rheumatol. 2004 Jul;31(7):1356-61
pubmed: 15229957
Adv Drug Deliv Rev. 2021 Mar;170:113-141
pubmed: 33422546
Vaccine. 2020 Jan 22;38(4):847-851
pubmed: 31767465
J Am Acad Dermatol. 2021 May;84(5):1254-1268
pubmed: 33422626
Metabolites. 2021 May 25;11(6):
pubmed: 34070672
J Rheumatol. 2007 Feb;34(2):272-9
pubmed: 17304653
J Med Virol. 2021 Mar;93(3):1449-1458
pubmed: 32790106
Curr Opin Rheumatol. 2020 Sep;32(5):434-440
pubmed: 32675715
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Br J Dermatol. 2021 Sep;185(3):646-648
pubmed: 33982284
RMD Open. 2019 Sep 3;5(2):e001018
pubmed: 31565246
J Am Acad Dermatol. 2021 Jan;84(1):70-75
pubmed: 32926977
Dermatol Reports. 2020 Jun 25;12(1):8642
pubmed: 32655846
J Pers Med. 2021 Jun 19;11(6):
pubmed: 34205301
Clin Exp Dermatol. 2021 Aug;46(6):1106-1108
pubmed: 33666256
Infez Med. 2020 Mar 1;28(1):3-5
pubmed: 32009128
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
Crit Care. 2020 Apr 28;24(1):179
pubmed: 32345311
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e360-e361
pubmed: 32379913
Int J Dermatol. 2020 Aug;59(8):e267-e268
pubmed: 32557532
Dermatol Ther. 2020 Jul;33(4):e13708
pubmed: 32474988
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Lancet. 2020 Jun 6;395(10239):1763-1770
pubmed: 32442528
N Engl J Med. 2020 Jul 2;383(1):85-88
pubmed: 32348641
Vaccines (Basel). 2020 Dec 02;8(4):
pubmed: 33276686
Clin Exp Rheumatol. 2015 Mar-Apr;33(2):181-6
pubmed: 25738420
Ann Rheum Dis. 2021 Oct;80(10):1306-1311
pubmed: 33762264
J Allergy Clin Immunol. 2021 Jan;147(1):60-71
pubmed: 33075408
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Rheumatol. 2021 Sep;3(9):e627-e637
pubmed: 34258590